Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment

Wei, Zilun; Chen, Zhaoyang; Zhao, Yongchao; Fan, Fan; Xiong, Wei; Song, Shuai; Yin, Yong; Hu, Jingjing; Yang, Kun; Yang, Lirong; Xu, Baojun; Ge, Junbo

doi:10.1016/j.biomaterials.2021.121000

Cited by 85 publications

(72 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Then load miR-21 into it and build DDS. CD47-mediated signaling pathway can evade the clearance of macrophages, effectively internalize into cardiomyocytes, and inhibit cell apoptosis 147 ( Figure 5 A ).…”

Section: Construction Of Tumor-derived Extracellular Vesicles As Drug...mentioning

confidence: 99%

See 1 more Smart Citation

Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment

Xu¹,

Feng²,

Zhao³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are kinds of two-layer vesicles secreted by cells. They play significant roles in mediating component exchange between cells, signal transduction, and pathological development. Among them, the tumor-derived EVs (TDEVs) are found related to the tumor microenvironment and cancer development. TDEVs can be designed as a natural drug carrier with high tumor targeting and permeability. In recent years, drug delivery systems (DDS) based on TDEVs for cancer treatments have received considerable attention. In this review, the biological characteristics of TDEVs are introduced, especially the effect on the tumor. Furthermore, the various approaches to constructing DDS based on TDEVs are summarized. Then we listed examples of TDEVs successfully constructing treatment systems. The use of chemical drugs, biological drugs, and engineered drugs as encapsulated drugs are respectively introduced, particularly the application progress of active ingredients in traditional Chinese medicine. Finally, this article introduces the latest clinical research progress, especially the marketed preparations and challenges of clinical application of TDEVs.

show abstract

Section: Construction Of Tumor-derived Extracellular Vesicles As Drug...mentioning

confidence: 99%

“…A) Schematic illustration of the EVs modified with CD47 on membrane surface to achieve mononuclear phagocyte system blockade. Adapted with permission from 147 . Copyright Year 2021, Elsevier.…”

Section: Figurementioning

confidence: 99%

Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment

Xu¹,

Feng²,

Zhao³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…Anti-phagocytotic candidate molecules that can be inserted or expressed on the surface of exosomes include CD47, CD24, CD44, CD31, β2M, PD-L1, App1, and DHMEQ ( Parada et al, 2021 ). The time EVs stayed in the plasma doubled after CD47 modification, and improved biodistribution in targeted tissue was observed ( Wei et al, 2021 ). When EVs were recognized by macrophages, the activation of CD47-SIRPα pathway initiated immune evasion and reduced the phagocytosis of EVs ( Chao et al, 2012 ).…”

Section: Clinical Translation Of Exosome Therapymentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed

Wu¹,

Jin²,

Ding³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Microbial diseases are a global health threat, leading to tremendous casualties and economic losses. The strategy to treat microbial diseases falls into two broad categories: pathogen-directed therapy (PDT) and host-directed therapy (HDT). As the typical PDT, antibiotics or antiviral drugs directly attack bacteria or viruses through discerning specific molecules. However, drug abuse could result in antimicrobial resistance and increase infectious disease morbidity. Recently, the exosome therapy, as a HDT, has attracted extensive attentions for its potential in limiting infectious complications and targeted drug delivery. Mesenchymal stem cell-derived exosomes (MSC-Exos) are the most broadly investigated. In this review, we mainly focus on the development and recent advances of the application of MSC-Exos on microbial diseases. The review starts with the difficulties and current strategies in antimicrobial treatments, followed by a comprehensive overview of exosomes in aspect of isolation, identification, contents, and applications. Then, the underlying mechanisms of the MSC-Exo therapy in microbial diseases are discussed in depth, mainly including immunomodulation, repression of excessive inflammation, and promotion of tissue regeneration. In addition, we highlight the latest progress in the clinical translation of the MSC-Exo therapy, by summarizing related clinical trials, routes of administration, and exosome modifications. This review will provide fundamental insights and future perspectives on MSC-Exo therapy in microbial diseases from bench to bedside.

show abstract

“…Royo et al showed that neuraminidase treatment –a glycosidase that alters EVs surface glycosylation profile - induced an accumulation in the lungs compared with untreated EVs ( Royo et al, 2019 ). Moreover, since macrophages can take up EVs and clear them from the circulation, EVs can be engineered through the incorporation of CD47—a transmembrane protein that enables macrophages evasion -, which initiates a “don’t eat me” signal ( Imai et al, 2015 ; Kamerkar et al, 2017 ; Belhadj et al, 2020 ; Wei et al, 2021 ). Wei et al reported that CD47-enriched EVs remained more time in circulation when compared with unmodified EVs ( Wei et al, 2021 ).…”

Section: Extracellular Vesicles As a New Paradigm For Cell-free Therapymentioning

confidence: 99%

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Sanmartin

Borzone

Giorello

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide, with 10.0 million cancer deaths in 2020. Despite advances in targeted therapies, some pharmacological drawbacks associated with anticancer chemo and immunotherapeutic agents include high toxicities, low bioavailability, and drug resistance. In recent years, extracellular vesicles emerged as a new promising platform for drug delivery, with the advantage of their inherent biocompatibility and specific targeting compared to artificial nanocarriers, such as liposomes. Particularly, mesenchymal stem/stromal cells were proposed as a source of extracellular vesicles for cancer therapy because of their intrinsic properties: high in vitro self-renewal and proliferation, regenerative and immunomodulatory capacities, and secretion of extracellular vesicles that mediate most of their paracrine functions. Moreover, extracellular vesicles are static and safer in comparison with mesenchymal stem/stromal cells, which can undergo genetic/epigenetic or phenotypic changes after their administration to patients. In this review, we summarize currently reported information regarding mesenchymal stem/stromal cell-derived extracellular vesicles, their proper isolation and purification techniques - from either naive or engineered mesenchymal stem/stromal cells - for their application in cancer therapy, as well as available downstream modification methods to improve their therapeutic properties. Additionally, we discuss the challenges associated with extracellular vesicles for cancer therapy, and we review some preclinical and clinical data available in the literature.

show abstract

Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment

Cited by 85 publications

References 55 publications

Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment

Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment

Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Contact Info

Product

Resources

About